Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Sun Yat-sen University | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to confirm the protective effect and mechanism of anthocyanins on hyperuricemia patients with Cardiovascular disease.
Hyperuricemia patients who have the ability to complete the intervention study in the early stage of study were selected as the research subjects. A randomized controlled double blind control method was used to study the effect of one year of anthocyanins intervention. Serum UA levels, oxidative stress, AGEs, and endothelial function are detecting in patients with hyperuricemia who were treated with anthocyanins and placebo. Providing scientific basis of anthocyanins for the treatment with hyperuricemia and delaying atherosclerosis.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo capsule | Placebo Comparator | Simple hyperuricemia patients and with coronary heart disease in hospital. Double blind, randomized method. Control group taking placebo capsule |
|
| Anthocyanidins capsule | Experimental | Simple hyperuricemia patients and with coronary heart disease in hospital. Double blind, randomized method. The experimental group taking anthocyanins capsule. |
|
| Allopurinol | Experimental | The experimental group taking allopurinol. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Anthocyanidins capsule | Dietary Supplement | Continuous intervention for 1 years, detect the indicators in the intervention of 0,6,12 months |
|
| Measure | Description | Time Frame |
|---|---|---|
| Measurement of serum uric acid levels in all patients | Serum uric acid (mg/dl) is determined by Uric Acid kit on an automated system. | up to 1 months |
| Measure | Description | Time Frame |
|---|---|---|
| Measurement of advanced glycation end products and its receptor level in all patients | Advanced glycation end products and its receptor level are determined by high efficiency liquid chromatography. | up to 2 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Hui Dai | Contact | 020-36653321 | daihui66@sina.com | |
| Yuan Zhang | Contact | 020-61653566 | 1035834805@qq.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| General Hospital of Guangzhou Military Command of People's Liberation Army | Recruiting | Guangzhou | Guangdong | 020 | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 15198963 | Background | Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004 Jun 15;109(23 Suppl 1):III27-32. doi: 10.1161/01.CIR.0000131515.03336.f8. | |
| 2519996 | Background | Gimbrone MA Jr. Endothelial dysfunction and atherosclerosis. J Card Surg. 1989 Jun;4(2):180-3. doi: 10.1111/j.1540-8191.1989.tb00275.x. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo capsule | Dietary Supplement | Continuous intervention for 1 years, detect the indicators in the intervention of 0,6,12 months |
|
| Allopurinol | Drug | Continuous intervention for 1 years, detect the indicators in the intervention of 0,6,12 months |
|
| 11827916 | Background | Verma S, Anderson TJ. Fundamentals of endothelial function for the clinical cardiologist. Circulation. 2002 Feb 5;105(5):546-9. doi: 10.1161/hc0502.104540. No abstract available. |
| 22524108 | Background | D'Marco L, Garcia I, Vega C. [Uric acid, atherosclerosis and vascular calcifications in chronic kidney disease]. Invest Clin. 2012 Mar;53(1):52-9. Spanish. |
| 18946066 | Background | Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008 Oct 23;359(17):1811-21. doi: 10.1056/NEJMra0800885. No abstract available. |
| 19833602 | Background | Li C, Han L, Levin AM, Song H, Yan S, Wang Y, Wang Y, Meng D, Lv S, Ji Y, Xu X, Liu X, Wang Y, Zhou L, Miao Z, Mi QS. Multiple single nucleotide polymorphisms in the human urate transporter 1 (hURAT1) gene are associated with hyperuricaemia in Han Chinese. J Med Genet. 2010 Mar;47(3):204-10. doi: 10.1136/jmg.2009.068619. Epub 2009 Oct 14. |
| ID | Term |
|---|---|
| D002318 | Cardiovascular Diseases |
| D033461 | Hyperuricemia |
| ID | Term |
|---|---|
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D000872 | Anthocyanins |
| D000493 | Allopurinol |
| ID | Term |
|---|---|
| D005419 | Flavonoids |
| D002867 | Chromones |
| D001578 | Benzopyrans |
| D011714 | Pyrans |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006027 | Glycosides |
| D002241 | Carbohydrates |
| D010860 | Pigments, Biological |
| D001685 | Biological Factors |
| D011687 | Purines |
Not provided
Not provided